Recurrence or metastatic tumors are usually treated with androgen deprivation therapy (ADT) in the form of gonadotropin-releasing hormone (GnRH) and androgen receptor (AR) antagonists, so progression can be prevented and patient survival can be improved. The gene discussed is AR; the disease is metastatic neoplasm.